Models & Molecules

Steve Comeau | From novel binder design to the realities of AI in complex therapeutics

Generative models can now propose novel antibody sequences from antigen structure alone, but how far does that actually get you? In this episode, we sit down with Principal Scientist Steve Comeau to discuss what current models can realistically deliver, where the data falls short, and why the harder problems are still ahead of us. Read the full conversation: ⁠⁠https://enpicom.com/models-molecules/steve-comeau-from-novel-binder-design-to-the-realities-of-ai-in-complex-therapeutics/ [https://enpicom.com/models-molecules/jiwon-kim-from-lab-in-the-loop-to-zero-shot-the-role-of-cloud-and-ai-agents/]

Jiwon Kim | From lab-in-the-loop to zero-shot: The role of cloud and AI agents

Jiwon Kim, Product Lead at AWS AI Life Sciences, joins Models & Molecules to break down pharma’s digital shift: where cloud and software are becoming core infrastructure for modern drug discovery. We touch upon the potential of agentic AI, why zero-shot models are the future, why lab in the loop is the essential bridge for getting there. Read the full conversation: ⁠https://enpicom.com/models-molecules/jiwon-kim-from-lab-in-the-loop-to-zero-shot-the-role-of-cloud-and-ai-agents/ [https://enpicom.com/models-molecules/jiwon-kim-from-lab-in-the-loop-to-zero-shot-the-role-of-cloud-and-ai-agents/]

Do Soon Kim | Navigating the convergence of tech and pharma

In this episode of Models & Molecules, Do Soon Kim, Head of Product at Xaira Therapeutics, discusses his journey in the biotech and AI sectors, emphasizing the importance of effective communication in fostering collaboration between different scientific disciplines. The conversation explores the potential of machine learning to reshape our understanding of intelligence and moving beyond the limits of human intuition to decode complex biology. Read the full interview: https://enpicom.com/models-molecules/do-soon-kim-navigating-the-convergence-of-tech-and-pharma/ [https://enpicom.com/models-molecules/do-soon-kim-navigating-the-convergence-of-tech-and-pharma/]

Jaap Goudsmit | From rabies to COVID: Antibody discovery in the age of AI

In this episode of Models & Molecules, Jaap Goudsmit, MD, PhD, immunologist, epidemiologist, and one of the scientific forces behind Crucell, the Dutch biotech acquired by Johnson & Johnson, explores the critical evolution of antibody research. Jaap reflects on the journey from traditional discovery to the complexities of modern drug development, highlighting the transformative role of AI and why high-quality training data is essential for the next generation of therapeutics. Read the full conversation: https://enpicom.com/models-molecules/jaap-goudsmit-from-rabies-to-covid-antibody-discovery-in-the-age-of-ai/

René Hoet | Taking risks and driving innovation in biopharma

In this episode of Models & Molecules, René Hoet reflects on game-changing technologies like phenotypic screening, the unique innovation dynamics of small biotechs versus large pharma, and the real-world impact of AI in antibody discovery. We touch upon bridging academia and industry and discuss why taking calculated risks is essential for the next breakthroughs in drug discovery. Read the full conversation here [https://enpicom.com/models-molecules/rene-hoet-taking-risks-and-driving-innovation-biopharma/].